CD152 [CTLA-4] (mouse):Fc (mouse) (rec.)

Catalog number: CHI-MF-110A4-C100
Brand: Chimerigen Laboratories
Packing: 100 ug
Other sizes: 500 ug
1 mg
Price: € 95.00
Expected delivery time: 7 days
Quantity:

Product specifications for - CD152 [CTLA-4] (mouse):Fc (mouse) (rec.)

Overview: 
Product group: Proteins / Signaling Molecule
Category: Proteins
Subcategory: Recombinant protein
Species: Mouse
Source: NS1 cells
Properties: 
Purity: >98% (SDS-PAGE)
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352202
Form supplied: Lyophilized from 0.2um-filtered solution in PBS.
Storage instructions: Store at -20°C
Scientific information: 
Scientific info: CD152 and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD152 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD152 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD152 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. CD152 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CD152 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CD152 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CD152 and CD28 can bind to the same ligands, CD152 binds to B71 and B72 with 20-100-fold higher affinity than CD28.
Swiss prot ID: NP_033973.2
Additional information: 
Synonyms: CHI-MF-110A4-C100; Chimerigen Laboratories; CTLA4 / CD152; CTLA4; IDDM12; GSE; GRD4; CTLA-4; CELIAC3; CD152; CD; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte antigen 4; cytotoxic T lymphocyte associated antigen 4 short spliced form; celiac disease 3; CD152 isoform; cytotoxic T-lymphocyte-associated protein 4
Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance: W. Steurer, et al.; J. Immunol. 155, 1165 (1995) Read more
CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice : E.A. Tivol, et al.; J. Immunol. 158, 5091 (1997) Read more
Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation: J.A. Gonzalo, et al.; J. Immunol. 166, 1 (2001) Read more
Recombinant Adenovirus Coexpressing Covalent Peptide/MHC Class II Complex and B7-1: In Vitro and In Vivo Activation of Myelin Basic Protein-Specific T Cells: J. Chen, et al.; J. Immunol. 167, 1297 (2001) Read more
Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion: A.L. Mellor, et al.; J. Immunol. 171, 1652 (2003) Read more
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance: A. Sanchez-Fueyo, et al.; Nat. Immunol. 4, 1093 (2003) Read more
In Vitro and In Vivo Evaluation of Staphylococcal Superantigen Peptide Antagonists: G. Rajagopalan, et al.; Infect. Immun. v72, 6733 (2004) Read more
Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitis: Y.P. de Jong, et al.; Internat. Immunol. 16, 205 (2004) Read more
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase: A.L. Mellor, et al.; Internat. Immunol. 16, 1391 (2004) Read more
A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity: R. Chakrabarti, et al.; Vaccine 23, 4553 (2005) Read more